Oncolytics Biotech

ONCY NASDAQ
1.660
+0.040
+2.47%
Closed 16:00 07/17 EDT
Open
1.640
Prev Close
1.620
High
1.670
Low
1.590
Volume
24.37K
Avg Vol (3M)
44.98K
52 Week High
5.47
52 Week Low
1.572
% Turnover
0.12%
Market Cap
33.70M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Oncolytics Biotech ONCY stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Oncolytics Biotech Inc. is a development-stage company. The Company is focused on the development of REOLYSIN, its cancer therapeutic. The Company's clinical program is made up of a registration program that includes muscle-invasive bladder cancer and glioma cancer, over six randomized Phase II clinical trials and approximately six other investigative clinical trials. The Company focuses on the registration of REOLYSIN in approximately two indications, including the neoadjuvant treatment of muscle-invasive bladder cancer and the treatment of glioblastoma. The Company has conducted a single arm United States Phase II non-small cell lung cancer (NSCLC) trial and a single arm United States Phase II pancreatic cancer trial for REOLYSIN. The Company is also engaged in conducting a Phase Ib trial for REOLYSIN and chemotherapy in combination with pembrolizumab in its Checkpoint Inhibitor Program.
MORE >

Recently

Name
Price
%Change